Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population
Isaksen et al.,
Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population,
medRxiv, doi:10.1101/2020.06.19.20135475 (Preprint)
Safety analysis in patients without COVID-19, finding a small increase in QTc associated with use of CQ, but not HCQ. Authors also study mortality (n=3,368), with HCQ hazard ratio 0.67 [0.43-1.05].
Isaksen et al., 22 Jun 2020, preprint, 5 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20135475; this version posted June 22, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care
population.
Jonas L. Isaksen, MSca, Anders G. Holst, MD, PhDb, Adrian Pietersen, MDd, Jonas B.
Nielsen, MD, PhDe, Claus Graff, MSc, PhDc, Jørgen K. Kanters, MDa
Affiliations:
a
Laboratory of Experimental Cardiology, Department of Biomedical Sciences, University of
Copenhagen, Copenhagen, Denmark.
b
c
Acesion Pharma, Copenhagen, Denmark
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
d
Copenhagen General Practitioners’ Laboratory, Copenhagen, Denmark
e
Division of Cardiovascular Medicine, Department of Internal Medicine, University of
Michigan, Ann Arbor, MI
Address for correspondence:
Jørgen K. Kanters, Department of Biomedical Sciences 10.5, Nørre Allé 14, 2200
Copenhagen N, Denmark. jkanters@sund.ku.dk, phone: +45 28757402
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20135475; this version posted June 22, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Abstract (325/350 words)
Background–Chloroquine (CQ) and Hydroxychloroquine (HCQ) have recently been
suggested as treatment for the current Corona Virus Disease 2019 (COVID-19) pandemic.
However, despite their long-term use and only few case reports on adverse effects, CQ
and HCQ are listed as a known risk of the lethal ventricular arrhythmia Torsade de Pointes
and their cardiac safety profile is being questioned. Thus, we aimed to investigate the
electrocardiographic and mortality effects of CQ and HCQ in a primary care population.
Methods–We used Danish health care registers and electrocardiograms (ECGs) from
primary care to define three studies. 1) A paired study of subjects with ECGs before and
during use of CQ/HCQ, 2) a matched ECG study of subjects taking CQ/HCQ compared to
controls, and 3) a mortality study on people taking HCQ matched to control. In both
matched studies, we adjusted for connective tissue diseases, use of QT-prolonging drugs,
and cardiac disease. We used the QTc interval as the marker for electrocardiographic
safety. In the mortality study, cases were followed from first claimed prescription until 300
days after estimated completion of the last prescription. 95% confidence intervals follow
estimates in parenthesis.
Results–Use of CQ was associated with a 5.5 (0.7;10) ms increase in QTc in the paired
study (n=10). In the matched study (n=28, controls=280), QTc was insignificantly
increased in subjects taking CQ by 4.7 (-3.4;13) ms.
With a ΔQTc of 1.0 (-5.6;7.5), use of HCQ was not associated with an increased QTc in
the paired study (n=32). In the matched study (n=172, controls=1,720), QTc also was not
different between groups (p=0.5). In the mortality study (n=3,368), use of HCQ was
associated with a hazard ratio of 0.67 (0.43;1.05).
Conclusions–In subjects..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit